...
首页> 外文期刊>Clinical nuclear medicine >Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation
【24h】

Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation

机译:131I-MIBG和舒尼替尼的联合治疗可从遗传性副神经节瘤-嗜铬细胞瘤综合征导致的转移性副神经节瘤患者的SDHB突变中缓解

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A 22-year-old woman with rapidly progressing metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome from an SDHB mutation, who recurred after neoadjuvant chemotherapy, was found to be MIBG avid. She was treated with 2 I-131-MIBG treatments and concurrent sunitinib, achieving a complete response. She was in full remission for 9 months before developing bone metastases.
机译:一名22岁的妇女因新的辅助化疗后复发,由于遗传性副神经节瘤-嗜铬细胞瘤综合征,由于遗传性副神经节瘤-嗜铬细胞瘤综合征而迅速发展,并伴有快速发展的转移性副神经节瘤。她接受了2次I-131-MIBG治疗,并发舒尼替尼,获得了完全缓解。在骨转移之前,她已经完全缓解了9个月。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号